Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:04:07.089Z.
Calculation as of: 2026-10-06T17:04:07.089Z.
Quote observation: 2026-10-06T17:00:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$271.90M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.03M
EV/EBIT Ratio
N/A
TTM Avg
11.31x
3Y Avg
11.31x
5Y Avg
15.93x
Market Cap
$266.50M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$265.41M
EV/EBIT Ratio
N/A
TTM Avg
5.32x
3Y Avg
26.78x
5Y Avg
44.78x
Market Cap
$264.73M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$276.14M
EV/EBIT Ratio
N/A
TTM Avg
102.60x
3Y Avg
102.60x
5Y Avg
102.60x
Market Cap
$262.65M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $269.92M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.90M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $267.03M | N/A | 11.31x | 11.31x | 15.93x |
| Fate Therapeutics, Inc. (FATE)vs › | $273.33M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.50M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $265.41M | N/A | 5.32x | 26.78x | 44.78x |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $276.14M | N/A | 102.60x | 102.60x | 102.60x |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $262.65M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | N/A | 162862.62x | 112489.16x | 112489.16x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
